Related Articles
Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
MicroRNA profiling of paediatric AML with <em>FLT-ITD</em> or <em>MLL</em>-rearrangements: Expression signatures and <em>in vitro</em> modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors
Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells <em>in vitro</em>
MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients
Meta‑analysis of the efficacy of venetoclax and azacitidine combination therapy and azacitidine monotherapy for treating acute myeloid leukemia